Comparative Pharmacology
Head-to-head clinical analysis: BRONKOSOL versus THEOLAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOSOL versus THEOLAIR.
BRONKOSOL vs THEOLAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular cAMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/mL. Maintenance: 400-600 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Category C
Category C
Bronchodilator
Bronchodilator